<DOC>
	<DOCNO>NCT00765661</DOCNO>
	<brief_summary>The purpose study demonstrate pharmacokinetics ( PK , measure amount medication blood sample ) safety new medicine , LCP-Tacro™ tablet , Prograf® capsule , drug commonly take transplant recipient prevent body reject transplanted kidney . LCP-Tacro tablet contain active ingredient ( tacrolimus ) Prograf capsule , tablet design release tacrolimus extend period take daily . LCP-Tacro investigational drug . This study evaluate level tacrolimus blood first two week kidney transplant patient randomly assign ( chance , like flip coin ) take either LCP-Tacro™ tablet ( tacrolimus ) daily Prograf® capsule twice daily . In addition , patient remain study drug 360 day order evaluate relative safety LCP-Tacro™ tablet compare Prograf longer period time .</brief_summary>
	<brief_title>Pharmacokinetics LCP-Tacro ( TM ) Once Daily And Prograf® Twice A Day Adult De Novo Kidney Transplant Patients</brief_title>
	<detailed_description>This study randomize , parallel-group , open label , multicenter study adult de novo kidney transplant patient demonstrate pharmacokinetics safety LCP-Tacro tablet Prograf capsule first 2 week kidney transplantation . In addition study compare efficacy safety LCP-Tacro Prograf additional 50 week kidney transplantation . Eligible patient randomize ( 1:1 ratio ) within 12 hour transplantation ( Day 0 ) receive either : 1 ) LCP-Tacro tablet orally daily ( QD ) morning , interval 24+/- hour dos , start 0.14 mg/kg ( start daily dose African-American patient 0.17 mg/kg ) , 2 ) Prograf capsule 2 equally divided dos African-American patient ( 0.2 mg/kg total daily dose ) recommend U.S. Prescribing Information ( Astellas Pharma US , April 2006 ) . Day 1 define day first morning dose study medication give within 48 hour transplantation . Subsequent dos study medication adjust maintain target whole blood tacrolimus trough level 7 20 ng/mL remainder pharmacokinetic phase study ( Day1 Day 14 ) . Twenty-four-hour pharmacokinetic assessment perform Days 1 , 7 , 14 . Following completion third final pharmacokinetic assessment morning Day 14 , patient enter maintenance phase ( Days 15 360 ) study remain assigned study medication Day 360 . Visits safety assessment tacrolimus trough level maintenance phase Days 42 , 90 , 120 , 180 , 270 , 360 . On Day 360 , patient place maintenance immunosuppressive regimen determine treat physician .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>Adult men woman least 18 year age recipients kidney transplant decease donor live donor receive first oral dose randomize study drug within 48 hour transplant surgery ( graft reperfusion ) Recipient transplant organ kidney Recipients kidney nonheart beat donor Recipients kidney ABO incompatible donor Recipients kidney cold ischemia time ≥ 36 hour Recipients bone marrow stem cell transplant Patients white blood cell count ≤ 2.8 x 109/L unless absolute neutrophil count ( ANC ) &gt; 1.0 x 109/L Patients aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) enzyme level &gt; 3 time upper limit normal 30 day prior transplant procedure Patients fail drug abuse screen Patients unable swallow study medication Patients incapable understanding purpose risk study , give write informed consent , unwilling comply study protocol Pregnant nursing woman ( woman childbearing potential must negative serum pregnancy test within seven day prior receive study medication ) Patients reproductive potential unwilling/unable use double barrier method contraception throughout duration study Patients treat investigational agent 30 day prior enrollment Patients hepatitis C virus ( HCV ) negative receive HCV positive ( HCV RNA polymerase chain reaction ( PCR ) HCV antibody ) donor kidney Patients seropositive human immunodeficiency virus ( HIV ) Patients current malignancy history malignancy ( within past 5 year ) , except basal nonmetastatic squamous cell carcinoma skin treat successfully Patients uncontrolled concomitant infection , systemic infection require treatment , unstable medical condition could interfere study objective Patients severe diarrhea , vomit , active peptic ulcer gastrointestinal disorder may affect absorption tacrolimus Patients know hypersensitivity tacrolimus Patients form current substance abuse , psychiatric disorder condition , opinion Investigator , may invalidate communication investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
</DOC>